All In Biotech

Drug Trial Radar · NCT00144105

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

A Randomised, Open Label, Active Controlled Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir Plus 100 mg or 200 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Comparison to 400 mg Lopinavir Plus 100 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Antiretroviral Therapy Naive Patients for 48 With Extension up to 156 Weeks

Last checked: Nov 20, 2026Latest source record: Nov 1, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 562 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

562

Actual

Start

Feb 2004

Primary completion

Nov 2006

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients

Conditions

  • HIV Infections

Interventions

  • TPV500mg/RTV200mgBIDDrug

  • TPV500mg/RTV100mgBIDDrug

  • LPV400mg/RTV100mgBIDDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint is the proportion of treatment responders at 48 weeks. A treatment responder is a patient with a viral load (VL) less than 50 copies/mL measured at two consecutive visits without prior rebound or change of ARV therapy.

Locations

81 sites in 15 countries. Site status is shown where the registry gives one.

  • Boehringer Ingelheim Investigational Site

    BsAs, Argentina

  • Fundacion Huesped

    Buenos Aires, Argentina

  • Hospital de Agudos Teodoro Alvarez

    Buenos Aires, Argentina

  • Hospital Posadas

    Haedo, Argentina

  • Boehringer Ingelheim Investigational Site

    Darlinghurst, New South Wales, Australia

  • St Vincents Hospital;

    Darlinghurst, New South Wales, Australia

  • Boehringer Ingelheim Investigational Site

    Liverpool, New South Wales, Australia

  • Boehringer Ingelheim Investigational Site

    Surry Hills, New South Wales, Australia

  • Boehringer Ingelheim Investigational Site

    Carlton, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • Boehringer Ingelheim Investigational Site

    South Yarra, Victoria, Australia

  • Unidade de Pesquisa Clínica (UPC) - AIDS

    Campinas - Sp, Brazil

  • Boehringer Ingelheim Investigational Site

    Curitiba - PR, Brazil

  • Boehringer Ingelheim Investigational Site

    Manguinhos - Rio de Janeiro - RJ, Brazil

  • Instituto de Crianca / Hospital das Clínicas-FMUSP

    Mooca / São Paulo, Brazil

  • Hospital Geral de Nova Iguaçu - Ministério da Saúde

    Nova Iguaçu - RJ, Brazil

  • Universidade Federal do Rio de Janeiro

    Rio de Janeiro - RJ, Brazil

  • Hospital Dia

    Sacoma - São Paulo, Brazil

  • Universidade Federal da Bahia-Unidade Docente Assistencial d

    Salvador - BA, Brazil

  • Boehringer Ingelheim Investigational Site

    Santos - Sp, Brazil

  • Hospital do Servidor Público Estadual de São Paulo

    São Paulo - Sp, Brazil

  • UNIFESP/ Hospital São Paulo- Univers. Federal de São Paulo

    São Paulo - Sp, Brazil

  • I.I. Emilio Ribas - Moléstias Infecciosas

    São Paulo - SP, Brazil

  • Instituto de Infectologia Emílio Ribas

    São Paulo - SP, Brazil

  • Centro de Referência e Treinamento - DST/AIDS

    Vila Mariana - Sao Paulo, Brazil

  • Downtown Infectious Diseases Clinic

    Vancouver, British Columbia, Canada

  • Boehringer Ingelheim Investigational Site

    Winnipeg, Manitoba, Canada

  • McMaster University Medical Centre

    Hamilton, Ontario, Canada

  • The Ottawa Hospital Riverside Campus

    Ottawa, Ontario, Canada

  • Canadian Immunodeficiency Research Collaborative Inc.

    Toronto, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Sunnybrook & Woman's College Health Science Centre

    Toronto, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Boehringer Ingelheim Investigational Site

    Whitby, Ontario, Canada

  • Montreal General Hospital - McGill University Health Centre

    Monteal, Quebec, Canada

  • Boehringer Ingelheim Investigational Site

    Montreal, Quebec, Canada

  • Montreal Chest Institute, McGill University Health Centre

    Montreal, Quebec, Canada

  • Boehringer Ingelheim Investigational Site

    Bogotá, Colombia

  • Hôpital Jean Verdier

    Bondy, France

  • Hôpital Bocage

    Dijon, France

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.